Language
English
Publication Date
9-23-2024
Journal
The Journal of Infectious Diseases
DOI
10.1093/infdis/jiae198
PMID
38657001
PMCID
PMC11420797
PubMedCentral® Posted Date
4-24-2024
Abstract
Background: Although antivirals remain important for the treatment COVID-19, methods to assess treatment efficacy are lacking. Here, we investigated the impact of remdesivir on viral dynamics and their contribution to understanding antiviral efficacy in the multicenter Adaptive COVID-19 Treatment Trial 1, which randomized patients to remdesivir or placebo.
Methods: Longitudinal specimens collected during hospitalization from a substudy of 642 patients with COVID-19 were measured for viral RNA (upper respiratory tract and plasma), viral nucleocapsid antigen (serum), and host immunologic markers. Associations with clinical outcomes and response to therapy were assessed.
Results: Higher baseline plasma viral loads were associated with poorer clinical outcomes, and decreases in viral RNA and antigen in blood but not the upper respiratory tract correlated with enhanced benefit from remdesivir. The treatment effect of remdesivir was most pronounced in patients with elevated baseline nucleocapsid antigen levels: the recovery rate ratio was 1.95 (95% CI, 1.40-2.71) for levels >245 pg/mL vs 1.04 (95% CI, .76-1.42) for levels < 245 pg/mL. Remdesivir also accelerated the rate of viral RNA and antigen clearance in blood, and patients whose blood levels decreased were more likely to recover and survive.
Conclusions: Reductions in SARS-CoV-2 RNA and antigen levels in blood correlated with clinical benefit from antiviral therapy.
Keywords
Humans, Adenosine Monophosphate, Alanine, SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment, RNA, Viral, COVID-19, Male, Female, Biomarkers, Middle Aged, Viral Load, Treatment Outcome, Adult, Coronavirus Nucleocapsid Proteins, Aged, Antigens, Viral
Published Open-Access
yes
Recommended Citation
Singh, Kanal; Rubenstein, Kevin; Callier, Viviane; et al., "SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir" (2024). Faculty, Staff and Students Publications. 8809.
https://digitalcommons.library.tmc.edu/baylor_docs/8809
Comments
Clinical trial registration: NCT04280705 (ClinicalTrials.gov).